Ibrutinib

Drug Profile

Ibrutinib

Alternative Names: IMBRUVICA; Imbruvica; Imuburubika; JNJ-54179060; PCI-32765

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Celera Genomics Group
  • Developer Foundation GIMEMA; Genentech; Janssen; Janssen Biotech; Lymphoma Academic Research Organisation; National Cancer Institute (USA); Northwestern University; OHSU Knight Cancer Institute; Pharmacyclics; Stanford University Medical Center; University of California, Davis; University of Leeds
  • Class 2 ring heterocyclic compounds; Antineoplastics; Antirheumatics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Preregistration MALT lymphoma
  • Phase III Diffuse large B cell lymphoma; Graft-versus-host disease; Non-Hodgkin's lymphoma
  • Phase II/III Pancreatic cancer
  • Phase II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; B cell lymphoma; CNS cancer; Follicular lymphoma; Hairy cell leukaemia; Multiple myeloma
  • Phase I/II Gastrointestinal cancer; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Phase I Cancer; Solid tumours
  • Preclinical Breast cancer; Colorectal cancer; Lymphoma
  • Discontinued Rheumatoid arthritis; Seasonal allergic rhinitis

Most Recent Events

  • 06 Dec 2016 Phase-II clinical trials in Graft-versus-host disease in USA (PO)
  • 06 Dec 2016 Efficacy and adverse events data from phase I/IIb trial in Graft-versus-host-disease presented at the 58th American Society of Haematology Annual Meeting (ASH-2016)
  • 05 Dec 2016 Efficacy and adverse events data from a phase I/Ib trial in Chronic lymphocytic leukaemia/Small lymphocytic lymphoma and Mantle cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top